At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
MSK researchers are studying a new CAR T cell therapy to treat acute myeloid leukemia (AML). They want to evaluate its safety and find the best dose of the new treatment. The adults and children in this study have AML that keeps growing even after treatment. The new CAR T cell therapy is called CD371-CAR-IL18.
- A Phase 3 Study Comparing Ruxolitinib/Tacrolimus/Methotrexate with Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease After a Stem Cell Transplant
Full Title A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203/INCB 18424-370)
Purpose
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor’s healthy immune cells see the recipient’s normal cells as foreign and attack them.
In this study, researchers want to see if giving ruxolitinib with tacrolimus and methotrexate before and after a stem cell transplant will prevent GVHD. Ruxolitinib is already used to treat GVHD. The people in this study are getting a stem cell transplant as treatment for blood cancer.
The researchers will compare this new approach to the standard treatment, which includes cyclophosphamide, tacrolimus, and mycophenolate mofetil after transplant. If you take part in this study, you will be randomly assigned to get one of these treatments:
- Ruxolitinib with tacrolimus and methotrexate before and after transplant
- Cyclophosphamide, tacrolimus, and mycophenolate mofetil after transplant
Who Can Join
To join this study, there are a few conditions. You must:
- Leukemia, Hodgkin lymphoma, or non-Hodgkin lymphoma that will be treated with a stem cell transplant.
- Have a suitable stem cell donor.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Miguel-Angel Perales’ office at 646-608-3757.
Protocol
25-075Phase
Phase III (phase 3)Disease Status
Newly Diagnosed & Relapsed/RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06615050ClinicalTrials.gov
-
The purpose of this study is to compare two different approaches to surgery for children and adults with osteosarcoma (bone cancer) that has spread (metastasized) to the lungs. Participants will be randomly assigned to one of two techniques:
-
Researchers want to see if adding cabozantinib to standard chemotherapy works better than chemotherapy alone for osteosarcoma. The people in this study include children, adolescents, and young adults with osteosarcoma that has not yet been treated.
-
Researchers want to find the highest dose of ECI830 that can be given safely in people with advanced cancer. The people in this study have breast cancer or other solid tumors that have spread beyond their original location.
-
Researchers in this study are assessing a combination of imaging and blood tests to find pancreatic cancer early. The people in this study have an increased risk of this cancer due to pancreatic cysts. They are planning to have surgery to remove the cysts and check them for cancer. It is hoped that the imaging and blood tests can detect pancreatic cancer early so people can avoid surgery.
- A Phase 3 Study Comparing Proton Craniospinal Radiation Therapy With the Usual Radiation Therapy for Leptomeningeal Metastasis
Full Title A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation Versus Involved-Field Radiotherapy for Patients with Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis (Radiate-LM) (NRG-BN014) (CIRB)
Purpose
Breast cancer and non-small cell lung cancer (NSCLC) can spread to the cerebrospinal fluid-filled space around the brain and spinal cord. This is called leptomeningeal metastasis (LM). The effects of LM on the nervous system can be very serious.
The current standard strategy employs x-rays to treat the brain and specific areas of the spine to relieve or prevent symptoms. This is called involved-field radiation therapy (IFRT).
In this study, researchers are comparing usual IFRT with proton craniospinal irradiation (pCSI). pCSI uses proton radiation to comprehensively treat the entire central nervous system space. This includes the cerebrospinal fluid, brain, and spinal cord.
This study is determining whether pCSI is better than IFRT to treat LM in people with breast cancer or NSCLC. If you take part in this study, you will be randomly assigned to get IFRT or pCSI.
Who Can Join
To join this study, there are a few conditions. You must:
- Have newly diagnosed LM from breast cancer or NSCLC.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information about this study, please call Dr. Yao Yu’s office at 908-542-3427.
Protocol
25-150Phase
Phase III (phase 3)Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT06500481ClinicalTrials.gov
- An Acupuncture Study for Historically Under-Represented Cancer Survivors with Chronic Musculoskeletal Pain
Full Title Researching the Implementation of Acupuncture for Chronic Musculoskeletal Pain in Diverse Underserved Cancer Survivors (ReIMAGINE)
Purpose
Many survivors of cancer develop joint and muscle pain after receiving treatments for their cancer.
Research has shown that acupuncture can help with pain, but prior studies did not include many people from certain backgrounds. Researchers are doing this study to see if acupuncture could also work for people who were not well-represented in previous research.
If you join this study, you will be randomly assigned to get acupuncture over 10 weeks or your usual care. You will fill out questionnaires about your symptoms, quality of life, and use of pain treatments. If you are in the usual care group, you can receive 10 vouchers for acupuncture after the study is over.
Who Can Join
To join this study, there are a few conditions. You must:
- Have completed treatment for cancer at least 1 month before starting the study.
- Be experiencing moderate to severe joint or muscle pain for 1 month or more.
- Not have previously received acupuncture for pain in the past 3 months.
Researchers will also ask other questions to see if you are able to join this study.
Contact
For more information, please email [email protected].
Protocol
24-305Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06814977ClinicalTrials.gov
-
The purpose of this study is to find the best dose of ABBV-383 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
-
Researchers are assessing a drug called rQNestin34.5v.2, for people with brain cancer that came back after treatment. The people in this study have a type of brain cancer called a glioma.